Parkman Healthcare Partners’s Fulcrum Therapeutics FULC Stock Holding History

Parkman Healthcare Partners’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-206,866	Closed	-$1.51M	–	88
2022 Q4	$1.51M	Sell	206,866 -28,519	-12%	-$186K	0.4%	63
2022 Q3	$1.9M	Sell	235,385 -27,304	-10%	-$195K	0.54%	57
2022 Q2	$1.29M	Buy	262,689 +98,236	+60%	+$960K	0.47%	53
2022 Q1	$3.89M	Sell	164,453 -85,653	-34%	-$1.21M	1.14%	34
2021 Q4	$4.42M	Sell	250,106 -88,690	-26%	-$1.76M	0.98%	32
2021 Q3	$9.56M	Buy	338,796 +192,407	+131%	+$3.65M	2.42%	15
2021 Q2	$1.53M	Buy	146,389 +20,651	+16%	+$209K	0.34%	67
2021 Q1	$1.48M	Buy	+125,738	New	+$1.55M	0.34%	67

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Parkman Healthcare Partners's FULC Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Fulcrum Therapeutics (FULC) in Q1 2023, closing a stake of 206,866 shares — an estimated $1.51M sold.

Parkman Healthcare Partners first reported a position in FULC in Q1 2021 and held it in 8 quarters. The position peaked at $9.56M in Q3 2021. 116 funds tracked by Wall St. Rank hold FULC as of Q1 2023.

Parkman Healthcare Partners reported no remaining Fulcrum Therapeutics position as of Q1 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 206,866 Fulcrum Therapeutics shares in Q1 2023, an estimated $1.51M.
Parkman Healthcare Partners first reported a position in Fulcrum Therapeutics in Q1 2021 and held it in 8 quarters.
Parkman Healthcare Partners's Fulcrum Therapeutics position peaked at $9.56M in Q3 2021.
116 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.